Skip to main content

A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA

Clinical Trial Grant
Duke Scholars

Administered By

Pediatrics, Medical Genetics

Awarded By

Amicus Therapeutics Corporation

Start Date

February 13, 2019

End Date

April 30, 2024
 

Administered By

Pediatrics, Medical Genetics

Awarded By

Amicus Therapeutics Corporation

Start Date

February 13, 2019

End Date

April 30, 2024